Joseph F. Grosso
75 works · 19,160 citations · h-index 29
Top works
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).
- Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
- Cutting Edge: An In Vivo Requirement for STAT3 Signaling in TH17 Development and TH17-Dependent Autoimmunity
- LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems
- Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
- Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells
- Eos Mediates Foxp3-Dependent Gene Silencing in CD4 + Regulatory T Cells
- CTLA-4 blockade in tumor models: an overview of preclinical and translational research.
- Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040.
- A role for the transcription factor Helios in human CD4+CD25+ regulatory T cells
- Tc17 CD8 T Cells: Functional Plasticity and Subset Diversity
- Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032.
- Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model
- Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies
- Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab.
- Radiotherapy augments the immune response to prostate cancer in a time‐dependent manner